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Recent months have witnessed many new developments in the field of Genetics and the subfields 
of Medical Genetics and therapeutics in particular. The foremost of these new developments is a 
unanimous ruling issued by the Supreme Court of the United States of America on June 13, 2013 
that the naturally occurring genes cannot be patented.  The ruling also invalidates all existing 
patents on such genes, but still allows the synthetic genes like copy DNA (cDNA) to be patented.  
The American College of Medical Genetics and the American Society of Human Genetics have 
hailed this decision as a victory for medical geneticists whose ultimate goal is to promote the 
medical diagnoses.  Although this ruling was in response to a specific court challenge to the 
patents for Breast Cancer Genes 1 and 2 (called BRCA1 and BRCA2) held by Salt Lake City 
based Myriad Genetics, Inc., all existing patents on genes like FLT3 [an integral part of the 
standard  of  care  for  acute  myelogenous  leukemia  (AML)  now],  RB1  gene  for  diagnosis  of 
melanoma, gene for prostate cancer, etc.  In 2005, an article in the journal Science estimated that 
20%  of  the  human  genes  had  been  patented,  of  which  63%  patents  were  held  by  private 
companies. With this ruling, as long as the researchers or diagnostic laboratories do not copy the 
exact procedures of the gene-patent holding laboratories/firms and instead, use alternate methods 
to  diagnose  gene  mutations  like  next  generation  sequencing,  whole  genome  analysis  or 
significantly modified cDNA strings, etc., they can now work on any naturally occurring gene.  
This will foster new methods for detecting gene mutations and help the medical community for 
better diagnoses of human disorders.  Some doctors, hospitals are already planning to bring in-
house  many  of  these  diagnostic  tests  instead  of  sending  the  patient  specimens  to  specific 
laboratories holding the gene patents.  Saving money on the exuberant prices charged by the 
gene patent holding laboratories, the doctors would be able to offer the same tests at much 
cheaper prices to the patients.  Currently, the Fluorescence in situ hybridization (FISH) probes 
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mutations.  Now, other laboratories will also be able to develop new FISH probes which may not 
be the exact copies of the existing probes (if they are also patented), and work on the same genes.  
The monopoly is over and this competition will also bring down the prices of the currently very 
expensive FISH probes. 
Based  on  the  cell-free  fetal  DNA  circulating  in  maternal  blood,  a  team  of  workers  have 
developed  a  noninvasive  paternity  testing  using  informatics  supported  analysis  of  single-
nucleotide polymorphism (SNP) array measurements to accurately determine paternity in early 
pregnancy (Ryan et al, 2013: Genetics in Medicine, 15: 473-81).  They achieved 100% accuracy 
in paternity testing using this new technology, as early as 6 weeks into pregnancy.  
 
A research team from University of California, Los Angeles (UCLA) has successfully used a 
microscopic  self-degradable  water-soluble  capsule  (pill)  to  deliver  apoptin  protein,  which 
effectively targets cancer cells to die without harming the non-cancerous healthy tissues.  The 
capsule used is less than half the size of the smallest bacteria and the researchers are predicting 
that it will open a door to an entirely new weapon against disease, as per the lead author Yi Tang, 
a UCLA professor of Chemical and Biomolecular Engineering.  
University of the South Wales reported in the journal Nature Structural and Molecular Biology 
(February 2013) that the so called junk DNA can reactivate tumor suppressor genes that can 
result  in  cancer  if  inactivated.    Their  research  shows  that  the  inactivation  of  these  tumor 
suppressor genes is not permanent.  The most noble tumor suppressor gene is TP53 gene on the 
short arm of chromosome 17, whose inactivation or a deletion (loss of heterozygosity, LOH) is 
associated with adverse prognosis for many types of leukemia and lymphoma, as well as solid 
tumors. Less than 2% of the whole genome is made up of actually functional genes and the 
remaining DNA was so far called Junk DNA, but now it is shown that it may not be junk after 
all, and may have regulatory functions for the transcribed genes.    
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